Drug research

GTX-102

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as apazunersen

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)NCT06617429	RARE	Phase 3	Active not recruiting	2026-07-10Actual
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)NCT07157254	RARE	Phase 2	Active not recruiting	2030-01Estimated
Long-term Extension of GTX-102 in Angelman SyndromeNCT06415344	RARE	Phase 3	Active not recruiting	2029-02Estimated

RAREActive not recruitingPrimary completion: 2026-07-10 · Actual

Trial details

RAREActive not recruitingPrimary completion: 2030-01 · Estimated

Trial details

RAREActive not recruitingPrimary completion: 2029-02 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.